open access

Vol 14, No 1 (2018)
Review paper
Published online: 2018-02-28
Get Citation

Immunotherapy of cancer — safety issues

Piotr Rutkowski
DOI: 10.5603/OCP.2018.0002
·
Oncol Clin Pract 2018;14(1):40-42.

open access

Vol 14, No 1 (2018)
REVIEW ARTICLES
Published online: 2018-02-28

Abstract

Using of immune checkpoints inhibitors, including mainly anti-PD-1, is a new, effective strategy of therapy of  advanced malignancies. In safety profile the main danger are autoimmunological adverse events, and their  management includes patient’s education, interdisciplinary cooperation, using diagnostic-therapeutic algorithms  and often immediate administration of corticosteroids. 

Abstract

Using of immune checkpoints inhibitors, including mainly anti-PD-1, is a new, effective strategy of therapy of  advanced malignancies. In safety profile the main danger are autoimmunological adverse events, and their  management includes patient’s education, interdisciplinary cooperation, using diagnostic-therapeutic algorithms  and often immediate administration of corticosteroids. 

Get Citation

Keywords

anti-PD-1, anti-CTLA-4, nivolumab, pmembrolizumab, ipilimumab, adverse, events, immunotherapy

About this article
Title

Immunotherapy of cancer — safety issues

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 1 (2018)

Article type

Review paper

Pages

40-42

Published online

2018-02-28

DOI

10.5603/OCP.2018.0002

Bibliographic record

Oncol Clin Pract 2018;14(1):40-42.

Keywords

anti-PD-1
anti-CTLA-4
nivolumab
pmembrolizumab
ipilimumab
adverse
events
immunotherapy

Authors

Piotr Rutkowski

References (16)
  1. Rutkowski P. Złośliwe nowotwory skóry. Wyd. 2. Via Medica .
  2. Rutkowski P. Nowe terapie w czerniakach. Via Medica .
  3. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016; 375(19): 1845–1855.
  4. Vanpouille-Box C, Lhuillier C, Bezu L, et al. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology. 2017; 6(11): e1373237.
  5. Thallinger C, Füreder T, Preusser M, et al. Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls. Wien Klin Wochenschr. 2017 [Epub ahead of print].
  6. Robert C, Ribas A, Wolchok J, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet. 2014; 384(9948): 1109–1117.
  7. Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26): 2521–2532.
  8. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4): 320–330.
  9. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine. 2015; 373(1): 23–34.
  10. Wolchok J, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2017; 377(14): 1345–1356.
  11. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017; 390(10105): 1853–1862.
  12. Haanen JB, Carbonnel F, Robert C, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv119–iv142.
  13. Weber JAS, Topalian SL, et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol 33, 2015 (suppl; abstr. ; 9018: 2015.
  14. Escudier B, Motzer RJ, Sharma P, et al. CheckMate 025 investigators, CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
  15. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2): 123–135.
  16. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627–1639.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl